132 related articles for article (PubMed ID: 32231200)
1. Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients.
Li L; Liu J; Xu M; Yu H; Lv C; Cao F; Wang Z; Fu Y; Zhang M; Meng H; Zhang X; Kang L; Zhang Z; Li J; Feng J; Lian X; Yu L; Zhou J
Cell Death Dis; 2020 Mar; 11(3):207. PubMed ID: 32231200
[TBL] [Abstract][Full Text] [Related]
2. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
Li N; Li H
J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
5. [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].
Wang SY; Zhao LN; Cheng H; Shi M; Chen W; Qi KM; Sun C; Wang X; Cao J; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):557-561. PubMed ID: 36709132
[No Abstract] [Full Text] [Related]
6. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN
Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.
Shang Q; Xue L; Lu A; Jia Y; Zuo Y; Zeng H; Zhang L
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):392-399.e5. PubMed ID: 38429221
[TBL] [Abstract][Full Text] [Related]
8. [CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].
Yan M; Wu YJ; Chen F; Tang XW; Han Y; Qiu HY; Sun AN; Xue SL; Jin ZM; Wang Y; Miao M; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):710-715. PubMed ID: 33113601
[No Abstract] [Full Text] [Related]
9. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():858590. PubMed ID: 35371098
[TBL] [Abstract][Full Text] [Related]
10. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
[TBL] [Abstract][Full Text] [Related]
11. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Shah BD; Bishop MR; Oluwole OO; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Holmes H; Arellano ML; Ghobadi A; Pagel JM; Lin Y; Cassaday RD; Park JH; Abedi M; Castro JE; DeAngelo DJ; Malone AK; Mawad R; Schiller GJ; Rossi JM; Bot A; Shen T; Goyal L; Jain RK; Vezan R; Wierda WG
Blood; 2021 Jul; 138(1):11-22. PubMed ID: 33827116
[TBL] [Abstract][Full Text] [Related]
12. [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].
Zuo YX; Jia YP; Wu J; Wang JB; Lu AD; Dong LJ; Chang LJ; Zhang LP
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):270-275. PubMed ID: 31104436
[No Abstract] [Full Text] [Related]
13. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
14. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
15. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
[TBL] [Abstract][Full Text] [Related]
16. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
Front Immunol; 2022; 13():934442. PubMed ID: 36110859
[TBL] [Abstract][Full Text] [Related]
17. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
18. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
19. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Schultz LM; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Rouce RH; Chinnabhandar V; Kunicki M; Barsan VV; Goksenin AY; Li Y; Mavroukakis S; Egeler E; Curran KJ; Mackall CL; Laetsch TW
J Clin Oncol; 2022 Mar; 40(9):945-955. PubMed ID: 34882493
[TBL] [Abstract][Full Text] [Related]
20. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]